Eli Lilly (LLY)
(Delayed Data from NYSE)
$776.38 USD
-29.68 (-3.68%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$776.38 USD
-29.68 (-3.68%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study
by Zacks Equity Research
Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.
Zacks Investment Ideas feature highlights: IonQ, E.L.F Beauty, Amazon, Meta Platforms and Eli Lilly
by Zacks Equity Research
IonQ, E.L.F Beauty, Amazon, Meta Platforms and Eli Lilly are part of the Zacks Investment Ideas article.
Here's How Much You'd Have If You Invested $1000 in Eli Lilly a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
4 Expert Tips for Navigating a Gap Down Market
by Andrew Rocco
Investors must learn to thrive in turbulent times. Stock Strategist Andrew Rocco provides 4 ways to hadle "tape bombs"
Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why
by Zacks Equity Research
Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.
Why Is Lilly (LLY) Up 6.4% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Franklin U.S. Large Cap Multifactor Index ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Novo Nordisk (NVO) Launches Wegovy in UK Amid Supply Issues
by Zacks Equity Research
Novo Nordisk (NVO) announces the controlled and limited launch of Wegovy in the U.K. amid rising demand for weight loss treatment and supply constraints.
Should Invesco S&P 100 Equal Weight ETF (EQWL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EQWL
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)
by Zacks Equity Research
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
Medicare's First Price Negotiation List Targets Expensive Drugs
by Kinjel Shah
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Novo Nordisk's (NVO) Shares Jump 17% in a Month: Here's Why
by Zacks Equity Research
Novo Nordisk's (NVO) commercial and pipeline progress with its popular obesity drug, Wegovy, continues to drive the share price momentum.
If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
The Zacks Analyst Blog Highlights Eli Lilly, UnitedHealth, Walmart, Applied Materials and BCE
by Zacks Equity Research
Eli Lilly, UnitedHealth, Walmart, Applied Materials and BCE are included in this Analyst Blog.
Top Research Reports for Eli Lilly, UnitedHealth & Walmart
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), UnitedHealth Group Incorporated (UNH) and Walmart Inc. (WMT).
Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca
by Zacks Equity Research
Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca are part of the Zacks Industry Outlook article
These 3 Large-Cap Pharma Stocks Have Been Red-Hot
by Derek Lewis
Large-cap pharmaceuticals have enjoyed buying pressure over the last month, delivering outsized gains to investors. And these three stocks have helped lead the charge.
5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace
by Kinjel Shah
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.
Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why
by Zacks Equity Research
Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.